NasdaqCM - Nasdaq Real Time Price USD

Adverum Biotechnologies, Inc. (ADVM)

2.4700
-0.0400
(-1.59%)
At close: June 4 at 4:00:01 PM EDT
2.5900
+0.12
+(4.86%)
After hours: June 4 at 5:10:25 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Laurent Fischer President, CEO & Director 1.12M -- 1964
Ms. Linda M. Rubinstein M.A. CFO, Principal Financial Officer & Principal Accounting Officer 713.24k -- 1967
Mr. Kishor Peter Soparkar J.D. Chief Operating Officer 725.62k -- 1971
Dr. Setareh Seyedkazemi Pharm.D. Chief Development Officer 705.62k -- 1974
Dr. Rabia Gurses Ozden M.D. Chief Medical Officer 795.1k -- 1969
Dr. R. Andrew Ramelmeier Ph.D. Chief Technology Officer -- -- 1962
Dr. Romuald Corbau Ph.D. Chief Scientific Officer -- -- 1969
Ms. Aneta Ferguson General Counsel -- -- --
Ms. Dena House Chief People Officer -- -- --
Ms. Carla Fiankan Senior Vice President of Regulatory Affairs -- -- --

Adverum Biotechnologies, Inc.

100 Cardinal Way
Redwood City, CA 94063
United States
650 656 9323 https://adverum.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
155

Description

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Corporate Governance

Adverum Biotechnologies, Inc.’s ISS Governance QualityScore as of June 1, 2025 is 8. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 11, 2025 at 10:59 AM UTC - August 15, 2025 at 12:00 PM UTC

Adverum Biotechnologies, Inc. Earnings Date

Recent Events

May 23, 2025 at 12:00 AM UTC

DEFA14A: Proxy Statements

May 14, 2025 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 28, 2025 at 12:00 AM UTC

DEFA14A: Proxy Statements

April 18, 2025 at 12:00 AM UTC

PRE 14A: Proxy Statements

April 15, 2025 at 12:00 AM UTC

10-K: Periodic Financial Reports

March 31, 2025 at 12:00 AM UTC

NT 10-K: Periodic Financial Reports

February 27, 2025 at 12:00 AM UTC

S-8: Offering Registrations

December 19, 2024 at 12:00 AM UTC

S-8: Offering Registrations

November 18, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 8, 2024 at 12:00 AM UTC

SC 13G: Tender Offer/Acquisition Reports

Related Tickers